Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04556032 · ClinicalTrials.gov registry record · NA
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT04556032: Clinical Trial NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
NCT04556032 is a NA study that was terminated before completion, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04556032, a NA study, was terminated before completion, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT L-Ergothioneine 10 mg/d
- DIETARY_SUPPLEMENT L-Ergothioneine 25 mg/d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
Why NCT04556032 stopped before completion
NCT04556032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04556032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04556032 about?
NCT04556032 is a clinical study titled "Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women". The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.
What is the current status of trial NCT04556032?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2020-09-09. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT04556032?
The interventions under investigation include: Placebo (OTHER), L-Ergothioneine 10 mg/d (DIETARY_SUPPLEMENT), L-Ergothioneine 25 mg/d (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04556032?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04556032's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI